TwinMed, LLC’s Post

Meet theravia team, Today, we introduce Adrien Phelipot, our Area Manager for MENA, APAC, and LATAM. Adrien Phelipot has more than 8 years of experience in the pharmaceutical industry, with expertise spanning Operations, Procurement, Marketing, and Sales. Since joining theravia, Adrien has been instrumental in managing and developing our presence in the MENA, APAC, and LATAM regions. Adrien's Words: "My role at theravia is to ensure that patients have access to life-saving treatments. This involves finding solutions to make therapies accessible and partnering with organizations that share our mission. Seeing the tangible impact of our work on patients' lives is incredibly rewarding." What Adrien Loves About theravia: "What I love the most about theravia is our team spirit, the diversity, and the flexibility of the company. These elements are crucial in successfully pursuing our mission. The collaborative environment allows us to innovate and adapt, ensuring that we can provide the best possible outcomes for those we serve." #theravia #MeetTheraviateam #GlobalHealth #PatientCare #Team #RareDiseases #NeglectedDiseases

Fenwick’s life sciences practice continues to demonstrate an unparalleled understanding of the industry, a fact celebrated in our 2023 Practice Group of the Year profile by Law360. 🌟 Operating at the intersection of tech and life sciences, the team has made significant strides in defending critical patents and steering major acquisitions that shape the sector's landscape, most recently guiding Shockwave Medical’s pending $13.1 billion acquisition by Johnson & Johnson and Alpine Immune Sciences, Inc.’ pending $4.9 billion acquisition by Vertex Pharmaceuticals. Law360 highlights the group’s work in defending essential patents for clients such as Novo Nordisk's Ozempic and facilitating the monumental $2.4 billion acquisition of DICE Therapeutics by Eli Lilly and Company. Dive deeper into our journey and explore the groundbreaking work that distinguishes us in the field of life sciences: https://lnkd.in/eYHqypca 🔬🧬 #FenwickforLifeSciences #PracticeGroupoftheYear #Innovation

New York's PE Healthcare Sector Weekly Round-up 🏥 📍 New Mountain Capital is selling ILC Dover to Ingersoll Road for about $2.3 billion. ILC Dover, established in 1947, specializes in designing and producing solutions for various markets including biopharma, pharmaceuticals, medical devices, and aerospace. The acquisition is anticipated to be finalized in the second quarter. 📍 WindRose Health Investors, based in New York, has successfully acquired SubjectWell. SubjectWell is a patient access company connecting patients with healthcare options, serving over 300,000 new patients monthly. WindRose's investment aims to expedite the development of new solutions and support healthcare companies requiring qualified patients for clinical trials. 📍 Charlesbank Capital Partners has created Kleer-Membersy, a US-based dental membership plan provider, through the merger of Kleer and Membersy. This strategic move consolidates market share and seeks to leverage growth opportunities in the dental industry. 📍 Permira has acquired Ergomed, a UK-based biopharmaceutical services company specializing in clinical research and trial management. The acquisition, valued at $886 million, represents the largest healthcare deal in the UK for the year. 📍 Kain Capital has invested in Essen Health Care, an independent multi-speciality healthcare provider with over 450 practitioners in New York. This marks Kain's third investment in primary care and multi-speciality care groups. 📍 Avel eCare, supported by Aquiline Capital Partners, has acquired Horizon Virtual, a Minnesota-based provider of virtual hospitalist services. This acquisition enhances Avel eCare's hospitalist services, a rapidly growing segment for the company. #privateequitynews #privateequity #healthcare #rawselection

Healthcare Sector's M&A Frenzy: A World Cup of Billion-Dollar Deals The last 12 months have been a whirlwind in the healthcare and pharmaceutical industry, with M&A totalling a staggering $378 Billion. The pace is not slowing down, as evidenced by the flurry of deals announced just this morning: $Johnson & Johnson (JNJ) makes a strategic move by acquiring Ambrx for a cool $2 Billion. $Merck (MRK) jumps into the fray, purchasing Harpoon Therapeutics (HARP) for $680 Million. $In a major play, Boston Scientific (BSX) scoops up Axonics (AXNX) for a hefty 3.7 Billion. $But the action doesn't stop there. In a surprising twist, NovaArtis enters the arena, taking over Calypso for $425 Million. These deals, especially JNJ's significant investment in Ambrx, mark just the beginning of the highly anticipated J.P. Morgan Healthcare Conference. This week is set to be a blockbuster, reminiscent of the excitement and unpredictability of the World Cup. Every player in the healthcare sector is on the edge, ready to make their move in the grand game of strategic acquisitions. What a first day of the championship!

Thoughts on this? >> Weeks after closing Bristol Myers deal, Karuna's ex-CEO heads to Blackstone-backed Anthos >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #biotech #pharma #healthcare

Thoughts on this? >> Weeks after closing Bristol Myers deal, Karuna's ex-CEO heads to Blackstone-backed Anthos >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #pharma #biotech

The 3️⃣ keys that have taken Ignasi Buch Mundó, Head of Product at Acellera Therapeutics, to the top of Product-Led Growth: - Prioritizing Product-market fit, then Data, then Growth. - Establishing the growth model, aligning the organization, and optimizing execution. - Developing trust for effective collaboration At the last #LPCxBCN, Ignasi shared his personal story and experience leading Product Growth throughout his remarkable professional career. 🚀 If you want to listen to the whole talk full of learnings and inspiration click on the link in comments. 👀👇 #productgrowth #PLG #producttalks

Creating a culture where employees can thrive is paramount to business success. On this episode of Making Waves our Chairman & CEO Hal Rosenbluth spoke with Peter Miller, a highly accomplished executive with an impressive track record in the pharmaceutical and healthcare industry about what it takes to to build a strong business model, and lessons learned as a CEO. Read, watch, or listen to this episode and more https://bit.ly/3TJA1zv #ceoinsights #culturematters #leadershipdevelopment #healthcareinnovation #healthcareexperts #makingwaves

From Cali to my home city…back-to-back events to meet and chat with folks in the industry. Misconception by many is that conferences are sales boiler rooms …approached with the mindset of pitching one’s company to as many people as possible…surface-level, repetitive, self-serving. “What keeps you up at night?” I spend the time listening to executives open up and tell me their personal aspirations, the struggles of the business and visions for the future. When you are in the business of solving problems…everyone needs your help. Be memorable. Be unique. Be authentic

📣 Exciting developments are unfolding at MDx CRO, and it is with great pleasure that I announce the addition of two exceptional talents to our leadership team: Nicholas Wilson and Kara McNair, stepping into roles as #PrincipalConsultants and reporting directly to me. Their names will be familiar to many of you, as both Nicholas and Kara are distinguished professionals with whom I've had the honor of collaborating previously. Our journey together has seen us overcome some of the most complex regulatory challenges faced by leading global companies in the #medicaldevice, #IVD, and #pharmaceutical sectors. The depth of our shared experiences has not only fostered innovative solutions but has also built a foundation of trust and mutual respect. It is a privilege to reunite with them at MDx CRO, especially at a pivotal moment in our organization's growth and expansion. The appointment of Nicholas and Kara signifies more than just the strengthening of our senior technical leadership; it means the expansion of our reach beyond geographical borders, notably marking the introduction of our first team member based in the #UK. As we gear up for the next phase of our journey, their insights, expertise, and leadership are set to catalyze our efforts in navigating the complexities of our industry. Please join me in welcoming Nicholas and Kara McNair to the MDx team. #TeamMDx #LeadershipExcellence #Innovation #GlobalReach #MedicalDevices #Pharma #IVD #NewBeginnings #PrecisionMedicine